Please login to the form below
Zaltrap
This page shows the latest Zaltrap news and features for those working in and with pharma, biotech and healthcare.
Rise in cancer therapy costs 'unsustainable' says oncologist
Saltz has been a vocal critic of cancer drug pricing for some time, and was one of the architects of MSKCC's decision three years ago not to prescribe Zaltrap ... Zaltrap was also turned down by the UK's National Institute for Health and Care Excellence
Latest news
-
England's Cancer Drugs Fund: Fixing a broken system
One of these has been Sanofi, whose prostate cancer drug Jevtana (cabazitaxel) and bowel cancer medicine Zaltrap (aflibercept) were deemed too expensive for both the specialist CDF and for NICE. ... Sanofi's Zaltrap (aflibercept):. second line treatment
-
Pharma condemns Cancer Drugs Fund cuts
Sanofi's Zaltrap is one of several drugs to be delisted from England's Cancer Drugs Fund. ... cancer. In the past 18 months there have been 1, 154 and 707 requests submitted to the CDF for Zaltrap and Jevtana respectively.
-
NHS names drugs to be re-evaluated for Cancer Drugs Fund
Prostate cancer. Zaltrap (aflibercept). Colorectal cancer. Takeda. Adcetris (brentuximab vedotin). Lymphoma (3 indications). .
-
Charity demands action on cancer drug prices in UK
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
-
England's Cancer Drugs Fund: Naughty or NICE?
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
The reality of real-world evidence
Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- 20 for 2020 – Five pharma companies to watch
- FDA approves Roche’s Actemra COVID-19 trial
- Moderna inks R&D agreements with Vertex and Chiesi
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
